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Abstract
Preterm infants are especially vulnerable to infection-induced white matter injury, associated with cerebral
palsy, cognitive and psychomotor impairment, and other adverse neurological outcomes. The etiology of such
lesions is complex and multifactorial. Furthermore, timing and length of exposure to infection also influence
neurodevelopmental outcomes. Different mechanisms have been posited to mediate the observed brain injury
including microglial activation followed by subsequent release of pro-inflammatory species, glutamate-induced
excitotoxicity, and vulnerability of developing oligodendrocytes to cerebral insults. The prevalence of such
neurological impairments requires an urgent need for early detection and effective neuroprotective strategies.
Accordingly, noninvasive methods of monitoring disease progression and therapy effectiveness are essential. While
diagnostic tools using biomarkers from bodily fluids may provide useful information regarding potential risks of
developing neurological diseases, the use of magnetic resonance imaging/spectroscopy has emerged as a promising
candidate for such purpose. Various pharmacological agents have demonstrated protective effects in the immature
brain in animal models; however, few studies have progressed to clinical trials with promising results.
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Introduction
In 1867, Virchow first described the pathological changes
in the neonatal brain, characterized by softening of the
periventricular white matter, and employed the term “con-
genital encephalomyelitis” where he emphasized the in-
flammatory nature of the disease [1]. In reference to the
same pathology, a new term was later introduced,
namely periventricular leukomalacia (PVL), by Banker
and Larroche in 1962 [2]. Volpe later noted that such
neurological anomaly is not only marked by the pres-
ence of periventricular white matter injury but is also
observed along with neuronal/axonal damage in the
brain including, but not limited to, areas of the cerebral
cortex, cerebral white matter, basal ganglia, and thalamus,
more appropriately introducing the term “encephalopathy
of prematurity” [3, 4].
There is evidence for an association between antenatal
infection with subsequent neurological injuries including
perinatal white matter injury, cerebral palsy, blindness,
deafness, and motor and cognitive deficits [5–10]. How-
ever, evidence has also emerged suggesting that antenatal
exposure to infection may not be directly associated with
increased risk of adverse outcomes [11–14] and may, in
fact, reduce the risk of death and neurodevelopmental def-
icits in the long run [15, 16]. To study such complex
effects of the interplay of timing and length of exposure to
inflammation and its consequences on neurodevelopment,
it is important to determine biomarkers that are specific,
robust, and detectable at an early stage. Animal models
have been used to study the associated risk factors for
adverse outcomes, both antenatal [17–23] and postnatal
[24, 25] with only a few available imaging studies.
Vulnerability of preterm infants to infection
In humans, maturation of the adaptive immune system
occurs after birth, thus making the innate immune sys-
tem largely responsible for fighting off infections in the
first weeks of life [26, 27]. However, as the innate im-
mune system develops around 24 weeks of gestation and
continues until term [28], premature infants may have a
reduced ability to respond to pathogens [26, 27, 29–31],
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characterized by reduced expression of surface innate
immune receptors, and/or immature intracellular down-
stream responses [32, 33]. Conflicting evidence has been
presented that the pro-inflammatory response in the ne-
onates may not necessarily be reduced, as observed with
similar or even higher levels of pro-inflammatory cyto-
kines detected in preterm neonates compared to term
neonates [34] or adults [35], but rather, a reduced anti-
inflammatory response [36–39] or dysregulation of the
immune system may play a major role in brain injury
[40]. The assessment of detailed inflammatory mecha-
nisms is essential in identifying robust markers that can
be used to detect brain injury.
Systemic inflammatory response possibly induces white
matter injury
Pro-inflammatory cytokines are upregulated in the brain
following peripheral lipopolysaccharide (LPS) adminis-
tration in animal studies; however, mechanisms of how
systemic inflammation relay signals to the brain that
leads to increased central nervous system (CNS) inflam-
mation and injury continues to be debated [41]. One
proposed mechanism is through the direct transport of
inflammatory agents or inflammatory cells across the
blood–brain barrier (BBB). Saturable transport systems
for pro-inflammatory cytokines in the BBB in mature
murine models have also been detected [42, 43], suggest-
ing that systemic pro-inflammatory cytokines may cross
the BBB to elicit brain inflammation. In 1993, Leviton
proposed that infection-induced upregulation of tumor
necrosis factor alpha (TNF-α) can produce brain injury
[44]. The hypothesis was supported by various studies
later demonstrating that placental production of pro-
inflammatory cytokines such as TNF-α [42], interleukin
(IL)-1α, IL-1β [45], and IL-6 [43] can cross the BBB. On
the other hand, systemic LPS given to P5 mice induces
marked microglia proliferation but with no evidence of
contribution of peripheral myeloid monocytes or granu-
locytes to the brain inflammation [46]. The proposition
that bacterial products, such as LPS, cross the BBB to
induce CNS inflammation directly is less likely as studies
show that systemic LPS was mostly found to be concen-
trated in the brain endothelial cells and not inside the
brain [47, 48].
Studies have suggested that the BBB may not develop
until birth, as it was assumed that such development
was associated with the appearance of astrocytes, which
do not appear until after birth [49, 50]. A group of scien-
tists recently suggested that BBB development may start
in earlier embryonic stages of development, based on
the evidence that pericytes, rather than astrocytes, may
be responsible for such process [51]. Difference in diffu-
sion characteristics of BBB between developing and the
mature brain has been noted, possibly due to the specific
fetal environment [52]. Such differences in structure/
morphological features may account for difference in
perfusion characteristics observed between adult and
premature infant barriers [52] and account for the in-
creased vulnerability of newborn brain to inflammation
[53].
Inflammation in the periphery may cause sustained
brain inflammation through an indirect mechanism
(Fig. 1). Brain endothelial cells express toll-like receptors
TLR-2, TLR3, TLR4, and TLR6 [54]. Circulating cells
may express or release TLR ligands that interact with
receptors present in brain endothelial cells that then
activate downstream signaling to induce inflammation in
the brain parenchyma. Indeed, TLR4 expression in CNS
cells was required for mediating brain inflammation in
response to systemic LPS in mice [55]. In addition, sys-
temic IL-1β may activate receptors on the brain endo-
thelium to induce prostaglandin E2 production in the
brain which in turn mediates inflammation [56].
Alternatively, the circumventricular organs (CVO)
(including the median eminence and adjacent neuro-
hypophysis, the organum vasculosum lamina termina-
lis, the subfornical organ, and the area postrema [57])
and the choroid plexus have been suggested to serve
as potential links between the CNS and peripheral
blood-borne substances and for an alternative route
for transfer of peripheral inflammatory signals to the
brain [58–62].
Understanding such inflammatory mechanisms in the
periphery is particularly helpful for purposes of finding
specific biomarkers that can be targeted for easy diag-
nosis and effective therapeutic options. However, while
cytokine detection in the periphery can have implica-
tions on inflammatory activities inside the brain, the
detection window for such fluctuations in inflammatory
cytokine levels may be narrow and unfortunately are
not specific of inflammatory brain injury [39]. Under-
standing inflammatory mechanisms within the brain
may provide a more specific target for finding the right
biomarker.
Mechanisms of brain injury
Brain injury observed in preterm neonates is likely multi-
factorial. However, inflammation, excitotoxicity, and im-
maturity of oligodendrocytes (OL) have been shown to
play important contributory roles in impairing normal
brain development. Microglial activation is at the corner-
stone of inflammatory brain injury in the preterm infant.
Implicated in a variety of developmental steps during brain
maturation, microglial cells regroup in the periventricular
zone, a main site with major axonal crossroads that corre-
sponds to white matter areas that are most vulnerable in
PVL, at the end of the second trimester [63, 64]. During
the last trimester, microglia are able to mediate a M1
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response characterized by the production of pro-
inflammatory cytokines and chemokines, reactive oxygen
and nitrogen species, excitatory amino acid, proteolytic
enzymes, along with phagocytic activity [65–67]. Such
pro-inflammatory response, suggesting M1 polarization
of microglia, is commonly associated with white matter
injury in response to cerebral insults [65, 68, 69]; the
inhibition of such activation reduced the severity of le-
sions in neonatal animal models [70]. The ability to de-
tect, in vivo, such shifts in microglia phenotype marked
by cytokine/chemokine upregulation would provide
highly meaningful diagnostic values for assessing brain
injuries. As detailed in a later section, positron emis-
sion tomography (PET) may provide such values in the
future. It is important to recognize that microglia also play
a role in mediating elimination of excess axons and pro-
moting neurogenesis and differentiation in the developing
brain [67]. The neuroprotective role of M2 differentiation,
associated with anti-inflammatory mechanisms, has been
noted in adult animal models. M2 polarization is associ-
ated with the expression of neuroprotective cytokines
such as TGF-β, IL-4, IL-10, and IL-13 [67]. Modulating
the microglia towards an anti-inflammatory phenotype
might be the key in reducing brain injury; obtaining tools
to follow microglial activity noninvasively would be tre-
mendously helpful.
Preterm infants have a high risk of developing white
matter lesions in response to perinatal injuries and
such injuries may be sensitized by previous exposure to
inflammation [71–73]. Glutamate, an excitatory neuro-
transmitter in the brain, can mediate excitotoxicity
through the activation of N-methyl-D-aspartate (NMDA),
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA), and kainate receptors [74]. Microglia activation
can be attributed to NMDA receptor activation in new-
born rodents through the use of selective receptor ago-
nists [70]. While the expression of NMDA receptors has
largely been investigated in the microglia, Manning et al.
[75] have demonstrated that NMDA receptor expression
is also detected in developing OLs in rats and humans.
The expression of NMDA and AMPA receptors on devel-
oping OLs, during a period in the OL lineage with in-
creased susceptibility, may contribute to white matter
injuries seen in the developing brain [75]. It was generally
accepted that premature OL (pre-OL) cell death due to
vulnerability to oxidative stress and excitotoxicity contrib-
uted to the observed white matter loss [76]. However,
emerging evidence has supported an alternative hypoth-
esis that pre-OL maturational arrest may be responsible
for the reduced myelination and subsequent white matter
injury observed in animal studies [77, 78] and in human
perinatal white matter injury [79]. The notion that failure
of OL lineage differentiation, rather than cell death, medi-
ates brain injury is supported by evidence of a prolifera-
tion of pre-OL pools following HI in white matter lesions
[77]. Impaired myelination can be evaluated noninvasively
with several tools using magnetic resonance imaging
(MRI) as detailed in a later section. Visible quantifiable
changes corresponding to mature myelinated fiber bun-
dles can be evaluated using MRI starting at 37 weeks of
gestation and be helpful to assess the impact of neuropro-
tective strategies.
Fig. 1 Immature immune response places preterm infants at higher risks of developing infection-induced sepsis that may lead to brain injury.
a and b represent conflicting evidence. TLR toll-like receptor, IL interleukin, TGF transforming growth factor, BBB blood–brain barrier, CVO
circumventricular organs
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Biochemical biomarkers for brain injury
Intra-amniotic infections are associated with an in-
creased risk of preterm delivery, which, in turn, may be
associated with neurological sequelae in former preterm
infants [80]. Microbial presence in the amniotic fluid
may elicit maternal and fetal inflammatory response that
are then responsible for neonatal complications. The as-
sociation between elevated inflammatory cytokines IL-1β
and IL-6 in the amniotic fluid and subsequent white
matter injury has been noted in preterm infants [81]. El-
evated levels of inflammatory cytokines in the cord
blood including IL-1β, IL-6 IL-8, and TNF-α have also
been shown to correlate with neonatal cerebral lesions
as detected by MRI after parturition in human prema-
ture infants [82]. Furthermore, clinical evidence shows
that elevated inflammatory response in the perinatal
period has been demonstrated to correlate with long-
term neonatal morbidities including cerebral palsy [83],
psychomotor deficits [8], and non-neurological diseases
including necrotizing enterocolitis (NEC) [84], bronch-
opulmonary dysplasia [85], and chronic lung disease
[86, 87] in preterm neonates. However, as previously
mentioned, antenatal exposure to infection may not ne-
cessarily be associated with an increased risk of adverse
outcomes [11–14] and may even have a precondition-
ing effect [15, 16] since antenatal assessment of inflam-
mation may be associated with a maternal response
during pregnancy and may not truly reflect inflamma-
tory response of the fetus. Dammann et al. [35] has
suggested that cord blood and postnatal serum cytokine
levels may reflect different waves of inflammatory re-
sponses in the fetal and neonatal circulation respectively
and that cytokine levels in the blood may change drastic-
ally in the postnatal period. Nelson et al. [14] demon-
strated that elevated inflammatory cytokines TNF-α, IL-1,
IL-6, IL-8, along with interferon-γ (IFN-γ), vasoactive in-
testinal peptide, substance P, and calcitonin gene-related
peptides in the neonatal blood correlated with PVL,
ventriculomegaly, and severe germinal matric hemorrhage
assessed by ultrasonography. Hecht et al. [88] also demon-
strated that the elevation of several blood proteins,
cytokines, and chemokine adhesion molecules was as-
sociated with white matter lesions. However, Kuban
et al. [89] has noted that transient elevation of any single
inflammation-associated cytokine in the blood did not
predict cerebral palsy, but recurrent elevation within the
first two postnatal weeks increased risk of adverse out-
comes in preterm infants. Interestingly, risks of diparesis
and hemiparesis were significantly increased when at least
four inflammatory blood proteins were elevated during
the first two postnatal weeks [89]. While these blood bio-
markers may potentially predict brain lesions in the pre-
term infants, Ellison et al. [90] reported that that plasma
levels of IL-6, IL-8, IL-10, TNF-α, and IFN-γ were not
associated with cerebral spinal fluids of these cytokines
nor did such plasma levels reflect brain injury as assessed
by MRI. It is suggested, however, that cerebral spinal fluid
(CSF) cytokine levels may be a more accurate predictor of
cerebral white matter injury as preterm infants with white
matter injury had higher CSF levels of IL-6, IL-10, and
TNF-α. While elevation of various blood markers has
been shown to be associated with white matter injury,
these markers are diverse in classification and not neces-
sarily predictive of white matter injury. Expression levels
of many of these blood biomarkers are intertwined, thus
making it difficult to pinpoint one biomarker that is spe-
cific for assessing brain injury. As mentioned previously,
dysregulation of the immune system [40], causing an
imbalance in the pro- and anti-inflammatory response,
suggests that more than one biomarker may be in-
volved in this process. In addition, the possibility of
other organ injuries may interfere with blood assess-
ments that reduce the accuracy in assessing brain injury
based only on biomarkers in bodily fluids. Such bio-
chemical assessments, however, may serve as useful
screening tools for preterm infants at high risks of de-
veloping adverse neurological diseases. The emergence
of the imaging techniques to assess brain injury has be-
come prevalent in the clinic; the use of imaging bio-
markers may provide a more accurate approach to
assess inflammation/injury that is more specific to the
brain.
Ultrasonography
In humans, the clinical use of cranial ultrasound in de-
tecting brain injury is the most prevalent technique used
due to its relative safety, convenience of bedside scans,
and cost-effectiveness that allows serial scanning of pre-
term infants at high risks [91] even if this technique is
known for its notable limitations. It is able to detect ven-
triculomegaly, peri/intraventricular hemorrhage, cystic
PVL [91, 92, 93], and cerebellar hemorrhages [91, 94].
However, cranial ultrasonography has reduced sensitivity
for diffuse white matter lesions in the context of PVL
whereas MRI and electroencephalography (EEG) may be
more sensitive at detecting mild white matter injury
[95–97] and with very little correlation with adverse
neurological outcomes [98, 99]
In animals, high-resolution ultrasound is now pos-
sible within the first few days of birth in rodents, but
this method quickly becomes limited due to skull calci-
fication. Using alternative view angle in older animals
offers better penetration without the need for scalp or
skull removal [100]. Using a short laser pulse that in-
duces a transient thermo-elastic expansion detected by
the ultrasound receiver, photoacoustic tomography of-
fers the ability to assess 2D coronal oxygen saturation
maps. In an animal model of PVL, this method was able
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to detect a significant reduction in oxygen saturation in
the corpus callosum, thus allowing for the monitoring
of physiological changes noninvasively [101].
Electroencephalography
Monitoring brain electrical activity can provide useful
information to evaluate brain injury in preterm infants.
EEG detects local field potentials produced by neurons
that fire off electrical activity [102]. Both traditional
EEG and amplitude-integrated EEG (aEEG), derived after
processing from raw EEG recordings, provide valuable in-
formation with regard to monitoring seizures, brain mat-
uration, and assessment of adverse neurological outcomes
[103, 104].
In pre-clinical studies
In a fetal sheep model of neuroinflammation [105],
where a bolus intravenous LPS injection is administered
directly to the fetus, typical hallmarks of white matter
injury were detected by MRI together with an increased
migroglia reaction (Fig. 2) and a reduction of OLs. In
this study, the impact of inflammation was shown to be
also associated with an impairment of a maturational
EEG increase compared to the control group, indicative
of reduced function of cortical neurons. In another fetal
sheep model, continuous low-dose infusion of LPS pro-
duced increased the number of activated microglia and
increased the number of TNF-α-positive cells in both the
periventricular white matter and the cortex along with an
impairment of normal EEG spectral edge frequency mat-
uration that seemed to be associated with the observed
inflammation in the LPS-exposed group [106].
In clinical studies
Wannabe et al. [107] suggests that serial recordings of
EEG have prognostic values in detecting timing and
mode of brain injuries in the preterm infants. A retro-
spective study by the group found that acute stage ab-
normalities, especially with EEG recordings performed
within 2 days of birth, marked by various degrees of
depression, strongly correlated with the severity of cere-
bral palsy [108]. Baud et al. [109], also in a retrospective
study, suggested that the observation of positive rolandic
sharpwaves in the rolandic regions (C3 and C4) within
7 days of birth correlated with severe PVL. Such waves
are characterized by a sharp and transient wave of less
than 500 ms in duration with a positive polarity. Oku-
mura et al. [110] observed abnormal EEG patterns in
preterm survivors with PVL in the early perinatal period
where serial EEG recordings were marked by an increase
in the number of frontal sharpwaves and occipital sharp-
waves. It was observed that frontal sharpwaves and oc-
cipital sharpwaves were present when positive rolandic
sharpwaves were not, indicating that the former two
may be more sensitive markers for white matter injury
and their sole presence may be useful in detecting less
severe forms of PVL. The use of EEG as a simple diag-
nostic tool for detecting brain injuries has become popu-
lar in the recent years among clinicians. Although its use
with respect to encephalopathy was mostly studied as a
result of hypoxia-ischemia (HI), its prognostic value in
predicting long-term outcomes has been noted [104,
111]. In a prospective study with 16 preterm infants
[112], the presence of intraventricular hemorrhage and
white matter damage was associated with prolonged
interburst intervals and lower aEEG amplitudes.
Fig. 2 Proposed mechanisms mediating peripheral inflammation and brain injury. Sepsis can overstimulate TLRs on endothelial (BBB/CVO) and/or
epithelial (choroid plexus) cells, which shift resting microglia to pro-inflammatory microglia that induce brain injury. PAM pathogen-associated
molecules, Poly:IC polyinosinic: polycytidylic acid, TLR toll-like receptor, LPS lipopolysaccharide, IL interleukin, IL-1R interleukin-1 receptor, TNF
tumor necrosis factor, NO nitric oxide, PGE2 prostaglandin E2
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Magnetic resonance imaging
MRI and magnetic resonance spectroscopy (MRS) have be-
come useful due to their high resolution and noninvasive
means of monitoring macrostructural, microstructural, and
metabolic developmental changes in the neonatal brain.
Identifying ongoing brain injury in the setting of infection/
inflammation will aid in recognizing newborns in need of
targeted neuroprotection. To date, there is clinical evidence
that MRI/MRS can identify early signs of injury along with
a growing body of experimental data on animals to support
such evidence.
Conventional imaging
Traditional magnetic resonance imaging, T1- and T2-
weighted imaging, allow in vivo and ex vivo assessment
of qualitative macrostructural changes in the brain and
can detect overt injury [113].
In pre-clinical studies, the ability to compare MRI
data and histology provides insights into associated
pathological changes following an inflammatory expos-
ure (Fig. 3). Dean et al. [105] found that LPS exposure
in fetal sheep induced cerebral injury, with T1 and T2
modifications seen 10 days after exposure, similar to
what is seen in preterm infants with periventricular
white matter injury. The distinguishing MRI features
include localized T1 hyperintensities and diffuse T2
hyperintensities. The former corresponds to dense
microglial activation, loss of neurofilaments, and accu-
mulation of amyloid precursor protein. The latter cor-
responds to white matter rarefaction, diffuse activated
microglia, increased apoptosis, and reduction of cells
expressing oligodendrocyte transcription factor. In vivo
assessment of signal changes in rat pups has shown, in
the white matter, an increase in the T2 relaxation time
constant, together with significant ventricular dilatation
4 days after LPS exposure [114]. However, if the assess-
ment is performed immediately after an inflammatory ex-
posure, conventional imaging may miss very early signs of
inflammatory brain injury. In contrast, diffusion-weighted
imaging and spectroscopy have shown extraordinary po-
tential as detailed below.
In clinical studies, early conventional imaging can reveal
more than periventricular cysts with early and sometime
persistent periventricular lesions with localized T1 hyper-
intensities as seen in the sheep model exposed to LPS
described earlier [115, 116]. In the setting of postnatal in-
fection, conventional MRI has shown increased cerebellar
hemorrhage [117].
Diffusion-weighted imaging
The apparent diffusion coefficient (ADC) is used as an
assessment of the Brownian motion of water molecules.
It is calculated from diffusion-weighted images. The re-
striction of water motion has been initially described in
adult animal stroke models [118] with similar findings in
neonatal studies [119, 120].
In pre-clinical studies, the natural evolution of the
ADC in the white matter has been quantified following
LPS exposure [114]. Similar to HI in neonatal rats [120]
and newborn term infants [121], the ADC has a biphasic
profile with an initial restriction of diffusion in the white
matter followed by an increase in diffusion 4 days after
LPS exposure in neonatal rats [24]. The initial restriction
of the ADC, measured 24 h after LPS exposure, was
shown to be associated with apoptosis measured by
fractin expression (Fig. 4a, b) [24]. Fractin is a caspase-
specific cleavage product of actin that serves as a novel
marker of apoptosis in brain injury. Yang et al. [122]
demonstrated the presence of caspase-cleaved actin as-
sociated to degenerating neurons and plaque-associated
microglia in Alzheimer’s disease and highlighted its role
in pathological processes. The presence of an intense
fractin immune-reactivity has been demonstrated in neur-
onal cell somas and dendrites [123]. In our study, there
was a significant anti-correlation between the degree of
ADC restriction and the natural logarithm of the fractin
Fig. 3 Coronal T1- and T2-weighted image with associated immuno-histochemistry of ex vivo fetal sheep brain exposed to lipopolysaccharide.
a T1 hyperintensity (arrowhead) with b histological staining using ionized calcium binding adaptor molecule 1 (Iba1) in the corresponding
area (arrowhead). c At higher magnification, the area shows dense macrophage-like microglia within the core of the periventricular white
matter lesions (arrowhead). Microglia surrounding the core lesion demonstrates amoeboid/activated morphology (black arrow). The dotted line
delineates the core of the lesion from the surrounding tissue. a and b are adapted from [105]
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expression surface in the corpus callosum (Fig. 4c, d). The
degree of ADC restriction, using noninvasive MRI, might
serve as a potential marker to quantify significant injury in
clinical settings and in animal experimentation. In human
preterm infants during the first few weeks of life, such
water diffusion restriction may be detected and was shown
to predict severe cystic PVL [124, 125].
Few days following LPS exposure, the ADC gradually
increases in animal studies. When compared to hist-
ology, the delayed increase in ADC has been associated
with increase in edema, tissue rarefaction, decreased cell
density, and increase in extracellular space [120, 126].
The radial diffusivity computed from diffusion tensor
imaging (DTI) acquisition is traditionally related to myelin
integrity as it measures diffusivity perpendicular to the
axon. Increase in white matter radial diffusivity has been
well described in mature animal model of multiple scler-
osis and shown to be a reliable marker of dysmyelination
[127]. However, the increase in radial diffusivity seen in
LPS-exposed animals at day 4 following LPS injection was
not attributed to myelination reduction but rather to
decreased cell density [114]. Similarly, newborn mice ex-
posed to IL-1β postnatally for 5 days and assessed 30 days
later had also an increased in radial diffusivity. Although,
there were fewer myelinated axons and the myelinated
ones had a normal myelin sheath in contrast to findings
described in adult animals [128]. Consequently, radial
diffusivity is clearly affected by inflammatory injury but
has to be interpreted in the context of the developing
brain.
In humans, the delayed increased in ADC of the white
matter has been shown in preterm infants imaged at
term equivalent age. Counsell et al. [129] and Maalouf et
al. [130] have demonstrated that, for preterm infants at
term equivalent age with overt white matter injury and
diffuse excessive high signal intensity on T2-weighted
images, the ADC values in the white matter regions in
the brain were significantly higher than for infants with
intact white matter. In the setting of post-natal infection
in preterm infants, diffusion imaging has revealed a
similar delayed increase in mean diffusivity and in-
creased radial diffusivity [117].
Tract-based spatial statistics
The development of user-independent approaches to
quantify the impact of therapy is essential. Recently, tract-
based spatial statistics (TBSS) has been identified as a po-
tential tool in this regard. Designed to study fractional
anisotropy maps compiled from DTI, TBSS is an approach
that evaluates microarchitectural differences between
groups in major fiber bundles. As the technique evaluates
diffusion characteristics of major fiber bundles, it is not
used as a specific tool to assess brain inflammation. TBSS
Fig. 4 Fractin labeling for apoptosis. Immunolocalization of fractin (a specific apoptosis neoepitope derived from caspase-cleaved actin) in animals
exposed to a 0.9 % sodium chloride (NaCl) or b lipopolysaccharide (LPS). Fractin labeling is intense in the corpus callosum of the LPS-treated
animal. c Coronal apparent diffusion coefficient (ADC) maps of animals exposed to 0.9 % NaCl or LPS showing a significant restriction of diffusion
in the corpus callosum (highlighted). d Anti-correlation between ADC and the natural logarithm of fractin expression in the corpus callosum.
Adapted from [24]
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is currently used in a prospective trial to test the efficiency
of melatonin to protect the preterm brain (see below).
Spectroscopy
Proton MRS (1H-MRS) may be used to investigate brain
metabolism and monitor development, which is character-
ized by a progressive increase in N-acetylaspartate (NAA)
(a marker of neuronal integrity and maturation) and myo-
inositol (a putative glial marker that also plays a role in
the neuronal signaling of the phosphoinositide pathway)
[131, 132]. An increased lactate level is indicative of anaer-
obic metabolism and mitochondrial dysfunction and was
also described in microglial activation [132, 133].
In human neonates, brain injury was shown to alter the
concentrations of NAA and lactate metabolites. In re-
sponse to HI, NAA/choline ratio was shown to decrease
[134] while lactate/choline ratio was shown to increase
[135]. In preterm infants exposed to infection, a similar re-
duction in NAA/choline ratio was shown [117].
In animal models of LPS-induced brain inflammation,
using very high magnetic field and short echo time, quan-
tifiable increase in lactate concentration using the LCMo-
del was also observed along with the appearance of lipid
13 [24], a peak corresponding to the methylene group
(−CH2–) which is known to increase with apoptosis.
The impact of inflammation in the brain can be moni-
tored in newborns and in equivalent animal models
using MRI/MRS/DTI. As there are to date no blood bio-
markers of cerebral integrity, the assessment of available
imaging biomarkers is essential for monitoring brain
injury and responses to therapy, but potentials and limi-
tations of such approaches need to be better delineated.
Placenta MRI
In pre-clinical studies As detailed earlier, pre-natal in-
flammatory exposure can modify the trajectory of brain
development in preterm infants. A growing research
domain of placental imaging may provide indications
about underlying disease mechanisms and potentially
serve as a useful biomarker. Pre-clinical studies have
shown that in a murine model of placental inflamma-
tion, induced by systemic LPS administration, a reduc-
tion of T2-weighted intensity could be detected as early
as 3–6 and 12 h after LPS exposure followed by a re-
duced placental perfusion seen by dynamic contrast-
enhanced (DCE) T1-weighted imaging 12 h after LPS
exposure [136]. In a landmark study using a rabbit
model of placental uterine ischemia, DCE MRI was
shown to correlate strongly with perfusion assessment
using fluorescent microspheres but unfortunately sys-
tematically underestimated placental perfusion [137].
In clinical studies Using conventional imaging, placental
hemorrhages and ischemic lesions were detected by T1-
and T2-weighted imaging but not chorioamnionitis [138].
In a case–control study using diffusion-weighted imaging,
Sohlberg et al. extracted placental perfusion fraction and
showed a strong correlation with ultrasound estimates
[139]. The various aforementioned MRI techniques show
the potential to provide insights for assessing placental
complications. While evidence has shown that complica-
tions during pregnancy may provide both preconditioning
and damaging sequelae to the fetal and neonatal brain, ad-
vancement in in vivo assessments during pregnancy may
help to differentiate the two conditions.
Positron emission tomography
PET allows for a noninvasive evaluation of microglia
activation in the diseased brain. The technique takes
advantage of the fact that the peripheral benzodiazepine
receptor is primarily found on activated microglia and
such receptors are capable of binding to radioactive li-
gands, which are in turn detectable using PET [140].
Hannestad et al. [141] found an increase in peripheral
benzodiazepine receptor binding in baboon brains 1 and
4 h after receiving intravenous LPS in vivo. In addition
to allowing for an evaluation of the timing of the inflam-
matory response, regional distribution of microglial acti-
vation was also computed in this particular study.
However, to date, such studies have not been performed
on human neonates and may be restricted to animal re-
search for concept development.
Therapeutic options
Pre-clinical studies
The role of IL-1β as a pro-inflammatory cytokine involved
in eliciting injury in the immature brain has been well
established through animal models [24, 25, 128, 142].
Thus, the therapeutic potential of IL-1 receptor antagonist
has been explored. Girard et al. [142] demonstrated that
postnatal administration of IL-1 receptor antagonist was
successful in improving motor and behavioral outcomes
after prenatal exposure to LPS along with reduced peri-
natal brain injury in rats. The use of IL-1 receptor antag-
onist has not been evaluated in preterm infants but has
been evaluated in adult humans with severe sepsis; how-
ever, results were not promising with no statistically
significant reduction of mortality [143]. Adult cerebral
parenchyma has a different vulnerability compared to the
newborn and, unfortunately, neuroprotection was not
evaluated in this study.
The neuroprotective properties of IL-10 have also
been demonstrated in premature animal models [144,
145]. Exogenous administration of IL-10 following LPS
exposure has been known to reduce sensorimotor de-
velopment impairment in the neonatal rat model [146]
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and offer neuroprotection by reducing brain injury in
neonatal mice model [147]. IL-10 pretreatment also re-
duced ibotenate-induced excitotoxic brain injury [148].
Furthermore, in neonatal rats exposed to maternal LPS,
IL-10 co-administered seemed to reduce white matter
injury in the neonatal rats [18, 149]. Thus exogenous
IL-10 might counteract the natural pattern of neonatal
microglial activation towards a M1 response.
Minocycline, a second-generation derivative of tetra-
cycline, has demonstrated anti-inflammatory and neu-
roprotective properties through suppressing microglial
activation, reducing white matter injury [150–152] and
improving neurobehavioral outcomes in premature ani-
mal models [153, 154]. In co-cultured microglia and
neurons from human fetal brains, minocycline inhibited
microglial activation and decreased cell death upon LPS
exposure [155].
Melatonin is a powerful endogenous antioxidant with
a high level of biosafety. Its efficacy in alleviating brain
injury through promoting myelination, reducing inflam-
mation, and reducing cell death has been demonstrated
in various premature animal models [156–159]. Fur-
thermore, the anti-oxidative and anti-inflammatory
properties of melatonin in various neonatal animal
models of NEC have shown to be effective in preven-
tion [160, 161].
The neuroprotective properties of erythropoietin, a
hematopoietic cytokine, have also been explored in the
neonatal animal models where it was observed to at-
tenuate microglial activation, reduce apoptosis, reduce
OL damage, and promote neurogenesis and repair
mechanisms [162–165].
Translating these strategies in human preterm infants
is challenging and in contrast to animal studies, true
neuroprotection assessment is complicated by the fact
that detailed tissue analysis is not available and that ac-
curate clinical evaluation can only be performed several
years later.
Clinical studies
In clinical trials, the administration of melatonin has
been shown to improve survival outcomes in septic term
neonates [166]. A neuroprotective trial testing melatonin
has been completed where TBSS was used as the main
approach to assess its effect [167]. Unfortunately, pre-
liminary results have not been conclusive [168]. This
raises the question whether melatonin at the given dos-
age was unsuccessful or if TBSS is a sufficiently mature
approach to evaluate the therapeutic response in these
settings. As mentioned earlier, TBSS is designed to test
only major fiber bundles, thus there is likelihood that a
positive effect in smaller bundles might be overlooked.
Recently, in a Swiss multicenter research trial, erythro-
poietin has neuroprotective properties in the preterm
babies. Leuchter et al. [169] showed that early high-dose
treatment of erythropoietin in preterm infants signifi-
cantly reduced the risk of white matter injury assessed at
term equivalent age using a semi-quantitative approach
on conventional MRI. Using a TBSS approach in the same
cohort, erythropoietin was found to increase fractional
anisotropy in major fiber bundles, a sign of increased
maturation [170].
Corticosteroids play an immunomodulatory role by re-
ducing the inflammatory response . However, clinical
studies with early administration of corticosteroids as
treatment for chronic lung disease in premature infants,
while showed short-term benefits in improved ventila-
tion, did not translate into long-term benefits [171]. In
preterm infants, the administration of dexamethasone
for the treatment of lung diseases has been shown to
produce long-term complications including cerebral
palsy [172], reduced cortical volume [173], and neurode-
velopmental impairments or death [174]. Hydrocorti-
sone, on the other hand, administered to premature
infants in the early postnatal period did not seem to be
associated with such long-term neurodevelopmental
impairment and cerebral palsy [175–177] and may
serve as a better alternative. Recently, in extremely pre-
term infants, an early and small dose of hydrocortisone
was shown to be safe and reduced the risk of chronic
lung disease, death, and patent ductus arteriosus
[178]. Nonetheless, further research is required to iden-
tify its potential benefits in the setting of ongoing brain
inflammatory injury.
Conclusions
The etiology of white matter lesions seen in preterm in-
fants is complex; various factors may predispose the im-
mature brain to such injuries. The activation of the
immune system is the body’s natural defense mechanism
in fighting off invasive pathogens. However, uncontrolled
response due to recurrent or severe infection may pro-
duce deleterious consequences including multi-organ
failure, brain injury, and increased mortality. Various
biochemical biomarkers have been shown to associate
with brain injury in the preterm infants; however, there
has yet emerged a single robust blood biomarker that is
employed in clinical settings today. The emergence of
imaging biomarkers as a noninvasive and sensitive diag-
nostic tool for early detection of cerebral white matter
injury is gaining acceptance. Pharmacological inter-
ventions in the form of synthetic drugs, recombinant
immunomodulators, and hormones have demonstrated
anti-inflammatory/protective effects in animal models,
however, with few promising candidates that have pro-
gressed to clinical trials. Further research is still required
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to come up with reliable tools to quantify noninvasively
inflammation and monitor therapeutic response.
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